{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:20:33Z","timestamp":1787509233245,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71315-4","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:03:42Z","timestamp":1729505022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The presence of oligoclonal bands predicts conversion to multiple sclerosis in isolated myelitis"],"prefix":"10.1038","volume":"14","author":[{"given":"Tobias","family":"Monschein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Krajnc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Zulehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Leutmezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zrzavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"71315_CR1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.60.4.730","volume":"60","author":"GC Rom\u00e1n","year":"2003","unstructured":"Rom\u00e1n, G. C. & Kerr, D. Proposed diagnostic criteria and nosology of acute transverse myelitis [6] (multiple letters). Neurology 60, 730\u2013731. https:\/\/doi.org\/10.1212\/WNL.60.4.730 (2003).","journal-title":"Neurology"},{"key":"71315_CR2","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1212\/WNL.0000000000004796","volume":"90","author":"NL Zalewski","year":"2018","unstructured":"Zalewski, N. L., Flanagan, E. P. & Keegan, B. M. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology 90, e96-102. https:\/\/doi.org\/10.1212\/WNL.0000000000004796 (2018).","journal-title":"Neurology"},{"key":"71315_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/1352458509345906","volume":"15","author":"J Young","year":"2009","unstructured":"Young, J. et al. Clinically isolated acute transverse myelitis: Prognostic features and incidence. Mult. Scler. 15, 1295\u20131302. https:\/\/doi.org\/10.1177\/1352458509345906 (2009).","journal-title":"Mult. Scler."},{"key":"71315_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/ene.14705","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh, G. et al. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. Eur. J. Neurol. 28, 1609\u20131616. https:\/\/doi.org\/10.1111\/ene.14705 (2021).","journal-title":"Eur. J. Neurol."},{"key":"71315_CR5","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","volume":"142","author":"M Filippi","year":"2019","unstructured":"Filippi, M. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain 142, 1858\u20131875. https:\/\/doi.org\/10.1093\/brain\/awz144 (2019).","journal-title":"Brain"},{"key":"71315_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00726","author":"F Deisenhammer","year":"2019","unstructured":"Deisenhammer, F. et al. The cerebrospinal fluid in multiple sclerosis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00726 (2019).","journal-title":"Front. Immunol."},{"key":"71315_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"71315_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/jnnp-2020-325274","volume":"92","author":"OC Murphy","year":"2021","unstructured":"Murphy, O. C. et al. Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis. J. Neurol. Neurosurg. Psychiatry 92, 831\u2013838. https:\/\/doi.org\/10.1136\/jnnp-2020-325274 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"71315_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2377-13-135","volume":"13","author":"\u00c1 Cobo Calvo","year":"2013","unstructured":"Cobo Calvo, \u00c1. et al. Idiopathic acute transverse myelitis: Outcome and conversion to multiple sclerosis in a large series. BMC Neurol. 13, 135. https:\/\/doi.org\/10.1186\/1471-2377-13-135 (2013).","journal-title":"BMC Neurol."},{"key":"71315_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/1352458517731911","volume":"24","author":"M Gastaldi","year":"2018","unstructured":"Gastaldi, M. et al. Predictors of outcome in a large retrospective cohort of patients with transverse myelitis. Mult. Scler. J. 24, 1743\u20131752. https:\/\/doi.org\/10.1177\/1352458517731911 (2018).","journal-title":"Mult. Scler. J."},{"key":"71315_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1191\/135248506ms1260oa","volume":"12","author":"J Bruna Escuer","year":"2006","unstructured":"Bruna Escuer, J. et al. Idiopathic acute transverse myelitis: A clinical study and prognostic markers in 45 cases. Mult. Scler. 12, 169\u2013173. https:\/\/doi.org\/10.1191\/135248506ms1260oa (2006).","journal-title":"Mult. Scler."},{"key":"71315_CR12","doi-asserted-by":"publisher","first-page":"100088","DOI":"10.1016\/j.nerep.2022.100088","volume":"2","author":"S Das","year":"2022","unstructured":"Das, S. et al. Radiological illusion of longitudinally extensive myelitis in multiple sclerosis. Neuroimmunol. Rep. 2, 100088. https:\/\/doi.org\/10.1016\/j.nerep.2022.100088 (2022).","journal-title":"Neuroimmunol. Rep."},{"key":"71315_CR13","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.msard.2019.101487","volume":"37","author":"S Asnafi","year":"2020","unstructured":"Asnafi, S. et al. The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. Mult. Scler. Relat. Disord. 37, 101487. https:\/\/doi.org\/10.1016\/j.msard.2019.101487 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"71315_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/WNO.0000000000000704","volume":"38","author":"L Leocani","year":"2018","unstructured":"Leocani, L., Guerrieri, S. & Comi, G. Visual evoked potentials as a biomarker in multiple sclerosis and associated optic neuritis. J. Neuro-Ophthalmol. 38, 350\u2013357. https:\/\/doi.org\/10.1097\/WNO.0000000000000704 (2018).","journal-title":"J. Neuro-Ophthalmol."},{"key":"71315_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.12865\/CHSJ.42.04.08","volume":"42","author":"L Calugaru","year":"2016","unstructured":"Calugaru, L., Calugaru, G. T. & Calugaru, O. M. Evoked potentials in multiple sclerosis diagnosis and management. Curr. Health Sci. J. 42, 385\u2013389. https:\/\/doi.org\/10.12865\/CHSJ.42.04.08 (2016).","journal-title":"Curr. Health Sci. J."},{"key":"71315_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207507.10.1212\/WNL.0000000000207507","author":"G Bsteh","year":"2023","unstructured":"Bsteh, G. et al. Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for MS. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000207507.10.1212\/WNL.0000000000207507 (2023).","journal-title":"Neurology"},{"key":"71315_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1468-1331.2008.02088.x","volume":"15","author":"J Sellner","year":"2008","unstructured":"Sellner, J. et al. Acute partial transverse myelitis: Risk factors for conversion to multiple sclerosis. Eur. J. Neurol. 15, 398\u2013405. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02088.x (2008).","journal-title":"Eur. J. Neurol."},{"key":"71315_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes, M. P. et al. 2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 20, 653\u2013670. https:\/\/doi.org\/10.1016\/S1474-4422(21)00095-8 (2021).","journal-title":"Lancet Neurol."},{"key":"71315_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177\u2013189 (2015).","journal-title":"Neurology"},{"key":"71315_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell, B. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 22, 268\u2013282 (2023).","journal-title":"Lancet Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71315-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T14:05:12Z","timestamp":1729778712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71315-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71315"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71315-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tobias Monschein: has participated in meetings sponsored by or received travel funding from Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Markus Ponleitner: has participated in meetings sponsored by or received travel funding from Amicus, Merck, Novartis and Sanofi-Genzyme. Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Janssen-Cilag, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. He has received financial support in the past 12\u00a0months by unrestricted research grants (Celgene\/BMS, Novartis). Nik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS\/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Gudrun Zulehner: has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Paulus Rommer: has received honoraria for consultancy\/speaking from AbbVie, Allmiral, Alexion, Biogen, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, has received research grants from Amicus, Biogen, Merck, Roche. Barbara Kornek: has received honoraria for speaking and for consulting from Biogen, BMS-Celgene, Johnson&Johnson, Merck, Novartis, Roche, Teva and Sanofi-Genzyme outside of the submitted work. No conflict of interest with respect to the present study. Thomas Berger: has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, BMS\/Celgene, Genesis, GSK, GW\/Jazz Pharma, Horizon, Janssen-Cilag, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva and UCB. His institution has received financial support in the past 12\u00a0months by unrestricted research grants (Biogen, Bayer, BMS\/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. Fritz Leutmezer: has participated in meetings sponsored by, received speaker honoraria or travel funding from Actelion, Almirall, Biogen, Celgene, Johnson & Johnson, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Tobias Zrzavy: has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24736"}}